In This Section

Advances in PH Journal

Home » Advances in PH Journal

Advances in Pulmonary Hypertension Autumn 2004 (Vol 3, No 3)

Editor's Memo
PHA Scientific Sessions Break New Ground, Providing Timely, Focused Venue for Current Research
Profiles in Pulmonary Hypertension
Juggling Roles of Patient Advocate and Director of a Leading Research Center, Robyn Barst Meets the Challenge
Exploring the Role of BMPR2 as Key Genetic Marker in Pulmonary Vascular Disease
The genetics of pulmonary arterial hypertension is a rapidly growing investigative area that has witnessed significant advances in the past few years. A heritable form of pulmonary hypertension, familial primary pulmonary hypertension, was first recognized in 1948.
Why Potassium Channel Dysfunction May Be ‘Missing Link’ in Pathophysiology of PAH
Potassium (K+) channel dysregulation in pulmonary artery smooth muscle cells (PASMCs) is important in understanding the etiology of pulmonary arterial hypertension (PAH), which is characterized by abnormalities in the vascular biology of the pulmonary circulation at all levels from lumen to adventitia.
Medical Treatment Options/Advances in Portopulmonary Hypertension: How the Spectrum Is Expanding
Portopulmonary hypertension is defined as the presence of an elevated pulmonary artery pressure (PAP; resting mean PAP >25 mm Hg or exercise PAP >30 mm Hg), with a normal pulmonary capillary wedge pressure in the presence of portal hypertension.
Pulmonary Hypertension Roundtable
Recapping Highlights from Pulmonary Hypertension Association Scientific Sessions and Identifying Key Issues Driving Translational Research

In This Section

Advances in PH Journal

Related Resources

Charles Burger, MD